BEACONSANDEGG
Financiado
Mechanobiology of cancer progression
Invasive cancers are a leading cause of death worldwide, with almost ten million deaths per year caused by resistance to antitumor treatments. In breast cancer, aggressiveness correlates with fibrotic stiffening of the tumour. The...
Invasive cancers are a leading cause of death worldwide, with almost ten million deaths per year caused by resistance to antitumor treatments. In breast cancer, aggressiveness correlates with fibrotic stiffening of the tumour. There is an urgent need to understand how the fibrotic microenvironment evolves, to design better targeted cancer therapies. Fibrotic stiffening is caused by fibroblasts secretion of a matrix with mechanical properties that stabilise the tumour vascular network. However, the hierarchy and stability of the tumour vascular network are not reproducible in vitro. To advance the field, I will develop a revolutionary platform able to recapitulate tumour fibrosis by exploiting the vascularisation of a living organism.To achieve my goal, I will use human breast cancer cells adhering to 3D polymeric micro scaffolds to create arrays of tumour micro environments. I will implant the arrays in vivo in the chorioallantoic membrane of an embryonated avian egg, to elicit a foreign-body fibrotic reaction. I will vary the micro scaffolds geometry to condition tumour infiltration by the host’s vessels and cells. I will exploit fluorescent spatial beacons incorporated in the micro scaffolds for multiphoton image correlation, to derive morphological and functional information of the regenerated fibrous matrix and vessels. I will predict mass transport of solutes and anticancer agents by computational modelling. To validate the platform, I will quantify in vivo the dose-dependent efficacy and cancer specificity of therapeutic agents whose success is known to depend on the fibrotic stage of tumours.This project combines mechanobiology to bioengineering, biomechanics, oncology, genetics, microtechnology, intravital imaging, biophysics and pharmacology to understand the progression mechanisms of the most incurable cancers. It will also provide an ethical and standardizable testing platform to boost the clinical translation of new therapeutic products in oncology.
ver más
Duración del proyecto: 59 meses
Fecha Inicio: 2022-09-01
Fecha Fin: 2027-08-31
Fecha Fin: 2027-08-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-09-01
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2021-ADG:
ERC ADVANCED GRANTS
Cerrada
hace 3 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
POLITECNICO DI MILANO
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5